Tokyo: Daiichi Sankyo's DATROWAY (datopotamab deruxtecan) has been approved in Japan for the treatment of adult patients with ...

PathAI's AIM-IHC Breast Panel is designed to address key challenges in breast cancer biomarker quantification, particularly the need for precise and reproducible assessment. The panel provides ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, ...

NEW YORK – The availability of AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for treating HER2-low breast cancer has shaken up long-established HER2 expression classification ...

PathAI, a leader in AI-powered pathology solutions, has launched the AIM-IHC Breast Panel, a suite of algorithms designed to quantify critical breast cancer biomarkers—HER2, ER, PR, and Ki-67.

Dec. 13, 2024 — A new screening method that combines laser analysis with a type of AI is the first of its kind to identify patients in the earliest stage of breast cancer, a study ...

Breast cancer classed as HER2-positive - defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease. However ...

PathAI launches the AIM-IHC Breast Panel, an AI-assisted tool for quantifying key breast cancer biomarkers, aiming to improve accuracy and efficiency in pathology labs. This development marks a ...

Breast cancer classed as HER2-positive – defined as an immunohistochemical (IHC) score of three or more – accounts for somewhere between 20% to 25% of all patients with the disease.